Navigation Links
Dermaseptins: Potent vaginal contraceptives

Safe and effective vaginal contraceptives are urgently needed. Ideally, such products should have antimicrobial and antiviral properties; as such, they could also play a role in the reduction of sexually// transmitted diseases (STDs), particularly the human immunodeficiency virus (HIV).

Most of the spermicidal products being marketed presently contain a detergent as an active ingredient, which do not provide any protection against STDs and that their effect in preventing HIV transmission remains controversial. Also, the repeated use of a surfactant as a vaginal contraceptive/microbicide has been associated with an increased risk of vaginal or cervical infection and irritation or ulceration. Because of this, it is important to identify and evaluate a new generation of contraceptive antimicrobial agents can be used vaginally in effective doses without causing overt vaginal irritation or other toxicity.

Antimicrobial peptides are produced by both prokaryotic and eukaryotic cells and have been the subject of many studies in recent years because of their involvement in host defense mechanisms and their potential use as therapeutic agents. These antimicrobial peptides include dermaseptins (DSs), a family of five structurally and functionally related peptides that were originally isolated from the skin of a tree-dwelling South American frog (Phyllomedusa sauvagei).

Recently, researchers from the Laboratory of Biochemistry, Faculty of Medicine, Sousse, Tunisia, thought that it would be interesting to develop a vaginal contraceptive with these compounds that have many biologic properties.

In their study, to be published in Contraception (available online 26 August 2005), the researchers set out to determine the effectiveness of two synthetic antimicrobial peptides, dermaseptin (DS1 and DS4) for inhibiting sperm motility. In addition, the mechanism of their spermicidal action was investigated and possible synergistic spermicidal effects exerted by EDTA were evaluated.

For the study, twenty samples of fresh semen were obtained from patients aged between 23 and 35 years. The data showed that sperm motility was inhibited with various concentrations of DS at different intervals ranging from 2 to 240 min. The action of DSs on sperm motility was observed to be dose dependent. Supplementation with pentoxifylline and that with calcium are known to enhance the motility of sperm but they did not prevent the spermicidal action of DSs.

This study indicates that DS is an effective agent to kill sperm. In view of this fact, it is suggested that DS4 has antibacterial, antiviral, antifungal and potentially spermicidal activities and could be a potent vaginal contraceptive.

However, the authors state that further studies are necessary to elucidate the mode of DS action, and suggest that considering the available information about contraceptive efficacy, the different biologic properties of these peptides should be studied as new candidates for human use as a barrier contraceptive agent with additional protection against STDs.
'"/>




Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. A Potent Sedative Kills Great-grandfather
11. Potential Benefits Of New Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... , ... March 28, 2017 , ... For many women, getting birth control isn’t as ... , meaning they either don’t have access to a health care facility or a pharmacy ... remote regions of the United States or for many who are faced with health or ...
(Date:3/28/2017)... Rochester, MN (PRWEB) , ... March 28, 2017 ... ... Elastography (MRE), is pleased to be invited to the Siemens Healthineers annual ... imaging professionals. The event will take place from March 27 - 31, ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, ... 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey and research ... the fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to advancing the science and clinical practice of radiosurgery, announced today the ... a multi-institutional, observational registry established to standardize data collection from patients treated ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a leading developer ... Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to ... with efforts by the American College of Surgeons, U.S. Department of Defense, Department ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 ... report, which provides an exhaustive study of the U.S. ... nearly 242 companies are functional in this market ... With the leading companies, such as GlaxoSmithKline Plc., ... focusing aggressively on various marketing strategies to increase ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global lifestyle drugs market to grow ... The report, Global Lifestyle Drugs Market 2017-2021, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology: